Claims for Patent: 10,059,925

Summary for Patent: 10,059,925

Title:	High titer recombinant influenza viruses with enhanced replication in vero cells
Abstract:	The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and genes from vaccine seed virus isolates which include a HA gene segment with a HA2 sequence encoding a HA2 that confers enhanced growth in cells in culture, such as Vero cells.
Inventor(s):	Kawaoka Yoshihiro, Horimoto Taisuke, Murakami Shin
Assignee:	Wisconsin Alumni Research Foundation (WARF)
Application Number:	US14816807
Patent Claims:

Details for Patent 10,059,925

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	August 31, 2005		2035-08-03
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	December 14, 2012		2035-08-03
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	October 05, 2006		2035-08-03
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	November 10, 2009		2035-08-03
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	August 15, 2013		2035-08-03
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	September 27, 2013		2035-08-03
Seqirus Pty Ltd.	AFLURIA, AFLURIA QUADRIVALENT	influenza vaccine	Injection	125254	September 28, 2007		2035-08-03